
Niloofar Rahmani
Examiner (ID: 12602, Phone: (571)272-4329 , Office: P/1625 )
| Most Active Art Unit | 1625 |
| Art Unit(s) | 1625, 1691, 1621 |
| Total Applications | 2303 |
| Issued Applications | 1739 |
| Pending Applications | 128 |
| Abandoned Applications | 466 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18552104
[patent_doc_number] => 20230250110
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-10
[patent_title] => DEUTERATED IRAK DEGRADERS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/008083
[patent_app_country] => US
[patent_app_date] => 2021-06-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 44107
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18008083
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/008083 | Deuterated IRAK degraders and uses thereof | Jun 2, 2021 | Issued |
Array
(
[id] => 20664795
[patent_doc_number] => 12606557
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-04-21
[patent_title] => Substituted indoles with inhibitory activity
[patent_app_type] => utility
[patent_app_number] => 17/927406
[patent_app_country] => US
[patent_app_date] => 2021-05-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 21323
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 186
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17927406
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/927406 | Substituted indoles with inhibitory activity | May 26, 2021 | Issued |
Array
(
[id] => 17563112
[patent_doc_number] => 20220127261
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-28
[patent_title] => RING DEUTERATED GABOXADOL AND ITS USE FOR THE TREATMENT OF PSYCHIATRIC DISORDERS
[patent_app_type] => utility
[patent_app_number] => 17/326270
[patent_app_country] => US
[patent_app_date] => 2021-05-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 57022
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -32
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17326270
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/326270 | Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders | May 19, 2021 | Issued |
Array
(
[id] => 17520457
[patent_doc_number] => 20220106306
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-07
[patent_title] => TYK2 INHIBITORS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/320394
[patent_app_country] => US
[patent_app_date] => 2021-05-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 79241
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17320394
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/320394 | TYK2 inhibitors and uses thereof | May 13, 2021 | Issued |
Array
(
[id] => 17134774
[patent_doc_number] => 11136320
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-10-05
[patent_title] => Fused ring derivative used as FGFR4 inhibitor
[patent_app_type] => utility
[patent_app_number] => 17/315481
[patent_app_country] => US
[patent_app_date] => 2021-05-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21638
[patent_no_of_claims] => 2
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17315481
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/315481 | Fused ring derivative used as FGFR4 inhibitor | May 9, 2021 | Issued |
Array
(
[id] => 17228574
[patent_doc_number] => 20210355130
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-18
[patent_title] => INHIBITORS OF NEK7 KINASE
[patent_app_type] => utility
[patent_app_number] => 17/315209
[patent_app_country] => US
[patent_app_date] => 2021-05-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27283
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17315209
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/315209 | Inhibitors of NEK7 kinase | May 6, 2021 | Issued |
Array
(
[id] => 19840120
[patent_doc_number] => 12252489
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-03-18
[patent_title] => Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
[patent_app_type] => utility
[patent_app_number] => 17/923160
[patent_app_country] => US
[patent_app_date] => 2021-05-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 49546
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 303
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17923160
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/923160 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | May 3, 2021 | Issued |
Array
(
[id] => 20535747
[patent_doc_number] => 12552811
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-02-17
[patent_title] => Immunosuppressant, and preparation method therefor and use thereof
[patent_app_type] => utility
[patent_app_number] => 18/010920
[patent_app_country] => US
[patent_app_date] => 2021-04-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17068
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 1238
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18010920
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/010920 | Immunosuppressant, and preparation method therefor and use thereof | Apr 29, 2021 | Issued |
Array
(
[id] => 18460338
[patent_doc_number] => 11684616
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-06-27
[patent_title] => Azalactam compounds as HPK1 inhibitors
[patent_app_type] => utility
[patent_app_number] => 17/246551
[patent_app_country] => US
[patent_app_date] => 2021-04-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 47496
[patent_no_of_claims] => 33
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 6
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17246551
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/246551 | Azalactam compounds as HPK1 inhibitors | Apr 29, 2021 | Issued |
Array
(
[id] => 17178313
[patent_doc_number] => 11155547
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2021-10-26
[patent_title] => Compounds for and methods of treating diseases
[patent_app_type] => utility
[patent_app_number] => 17/239375
[patent_app_country] => US
[patent_app_date] => 2021-04-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25867
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 236
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17239375
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/239375 | Compounds for and methods of treating diseases | Apr 22, 2021 | Issued |
Array
(
[id] => 17036612
[patent_doc_number] => 20210253570
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-19
[patent_title] => INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE
[patent_app_type] => utility
[patent_app_number] => 17/239362
[patent_app_country] => US
[patent_app_date] => 2021-04-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25460
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 425
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17239362
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/239362 | Indolizine derivatives and their application in medicine | Apr 22, 2021 | Issued |
Array
(
[id] => 20535721
[patent_doc_number] => 12552785
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-02-17
[patent_title] => Pyrazolo[1,5-a]pyridine derivative, preparation method therefor, and composition and use thereof
[patent_app_type] => utility
[patent_app_number] => 17/920630
[patent_app_country] => US
[patent_app_date] => 2021-04-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37907
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17920630
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/920630 | Pyrazolo[1,5-a]pyridine derivative, preparation method therefor, and composition and use thereof | Apr 21, 2021 | Issued |
Array
(
[id] => 18589132
[patent_doc_number] => 11738004
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-08-29
[patent_title] => Indomethacin analogs for the treatment of castrate-resistant prostate cancer
[patent_app_type] => utility
[patent_app_number] => 17/236694
[patent_app_country] => US
[patent_app_date] => 2021-04-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 24
[patent_no_of_words] => 18613
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 206
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17236694
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/236694 | Indomethacin analogs for the treatment of castrate-resistant prostate cancer | Apr 20, 2021 | Issued |
Array
(
[id] => 17050593
[patent_doc_number] => 20210260027
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-26
[patent_title] => METHODS FOR TREATING PULMONARY EMPHYSEMA USING SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C
[patent_app_type] => utility
[patent_app_number] => 17/234004
[patent_app_country] => US
[patent_app_date] => 2021-04-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 42456
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17234004
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/234004 | METHODS FOR TREATING PULMONARY EMPHYSEMA USING SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C | Apr 18, 2021 | Abandoned |
Array
(
[id] => 17314439
[patent_doc_number] => 20210403487
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-30
[patent_title] => NEW FORMS OF PYRIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES, ITS FORMULATION AND ITS PROCESS OF MAKING
[patent_app_type] => utility
[patent_app_number] => 17/233368
[patent_app_country] => US
[patent_app_date] => 2021-04-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16838
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17233368
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/233368 | Forms of pyrido[1,2-a]pyrimidin-4-one derivatives, its formulation and its process of making | Apr 15, 2021 | Issued |
Array
(
[id] => 18391304
[patent_doc_number] => 20230159522
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-25
[patent_title] => BCL-2 INHIBITOR
[patent_app_type] => utility
[patent_app_number] => 17/916845
[patent_app_country] => US
[patent_app_date] => 2021-04-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 106392
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -51
[patent_words_short_claim] => 520
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17916845
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/916845 | Bcl-2 inhibitor | Apr 13, 2021 | Issued |
Array
(
[id] => 16991740
[patent_doc_number] => 20210230160
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-29
[patent_title] => PHOSPHODIESTERASE INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/227597
[patent_app_country] => US
[patent_app_date] => 2021-04-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12304
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -43
[patent_words_short_claim] => 7
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17227597
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/227597 | Phosphodiesterase inhibitors | Apr 11, 2021 | Issued |
Array
(
[id] => 17156084
[patent_doc_number] => 20210317135
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-14
[patent_title] => RIP1K INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/221493
[patent_app_country] => US
[patent_app_date] => 2021-04-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23466
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -42
[patent_words_short_claim] => 277
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17221493
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/221493 | RIP1K inhibitors | Apr 1, 2021 | Issued |
Array
(
[id] => 17126152
[patent_doc_number] => 20210300920
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-30
[patent_title] => KRAS Mutant Protein Inhibitors
[patent_app_type] => utility
[patent_app_number] => 17/218568
[patent_app_country] => US
[patent_app_date] => 2021-03-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14761
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -1
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17218568
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/218568 | KRAS mutant protein inhibitors | Mar 30, 2021 | Issued |
Array
(
[id] => 19325956
[patent_doc_number] => 12043621
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-07-23
[patent_title] => Small molecule inhibitors of Interleukin-4
[patent_app_type] => utility
[patent_app_number] => 17/206542
[patent_app_country] => US
[patent_app_date] => 2021-03-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 24
[patent_figures_cnt] => 27
[patent_no_of_words] => 30219
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17206542
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/206542 | Small molecule inhibitors of Interleukin-4 | Mar 18, 2021 | Issued |